deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.
71Haider A, Yassin A, Doros G, Traish AM, Saad F: Reductions of weight and waist size in 362 hypogonadal men with obesity grades I to III under long-term treatment with testosterone undecanoate (TU): observational data from two registry studies. Endocr Rev 2014;35:21–24.
72Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al: Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest 2016;39:967–981.
73Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al: Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol 2016;174:R99–R116.
74Traish AM: Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes 2014;21:313–322.
75Zurlo F, Larson K, Bogardus C, Ravussin E: Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 1990;86:1423–1427.
76Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, et al: Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 2011;66:1090–1099.
77NCT02672592. Effects of Interleukin-1 Beta on Low Testosterone Levels in Men with Obesity and Metabolic Syndrome (TestIL). https://clinicaltrials.gov/ct2/show/NCT02672592.
78Pelusi C, Giagulli VA, Baccini M, Fanelli F, Mezzullo M, Fazzini A, et al: Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: a randomized, double-blind, placebo-controlled study. PLoS One 2017;12:e0183369.
79Bojesen A, Høst C, Gravholt CH: Klinefelter’s syndrome, type 2 diabetes and the metabolic syndrome: the impact of body composition. Mol Hum Reprod 2010;16:396–401.
80Calogero AE, Giagulli VA, Mongioì LM, Triggiani V, Radicioni AF, Jannini EA, et al: Klinefelter syndrome: cardiovascular abnormalities and metabolic disorders. J Endocrinol Invest 2017;40:705–712.
81Miller KK: Androgen deficiency: effects on body composition. Pituitary 2009;12:116–124.
82Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al: International Agency for Research on Cancer (IARC). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, IARC, 2017. globocan.iarc.fr.
83Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, et al: Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011;74:377–383.
84Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599–603.
85Owen PJ, Daly RM, Livingston PM, Fraser SF: Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis 2017;20:137–145.
86Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al: Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008;112:2188–2194.
87Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M: Guidelines on male hypogonadism. Eur Assoc Urol 2015. https://uroweb.org/guideline/male-hypogonadism/ (accessed: April 18, 2019).
88Elbers JM, Asscheman H, Seidell JC, Gooren LJ: Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999;276(2 Pt 1):E317–E325.
89Gooren LJ: Management of female-to-male transgender persons: medical and surgical management, life expectancy. Curr Opin Endocrinol Diabetes Obes 2014;21:233–238.
90Traish AM, Gooren LJ: Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med 2010;7:3758–3764.
91Velho I, Fighera TM, Ziegelmann PK, Spritzer PM: Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. Andrology 2017;5:881–888.
92Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al: The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014;171:P1–P29.
93Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al: Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab 2013;98:E628–E637.
94Pasquali R, Zanotti L, Fanelli F, Mezzullo M, Fazzini A, Morselli Labate AM, et al: Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective. J Clin Endocrinol Metab 2016;101:2013–2022.
95Poddar M, Chetty Y, Chetty VT: How does obesity affect the endocrine system? A narrative review. Clin Obes 2017;7:136–144.
96Escobar-Morreale HF, San Millán JL: Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266–272.
97Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1–7.
98Birzniece V: Doping in sport: effects, harm and misconceptions. Intern Med J 2015;45:239–248.
